Why Influencers Use the FDA to Bash Research Peptides

The FDA gets 65% of its drug review budget from the pharmaceutical companies whose drugs it reviews.

That number comes directly from the FDA's own budget justification to Congress. It is not a conspiracy theory. It is the funding structure created by something called PDUFA, the Prescription Drug User Fee Act, which is the law that lets pharmaceutical companies pay the agency that regulates them. The current application fee to have a drug reviewed is $4,198,000 per submission.

To understand why that matters, you need to understand what the FDA actually does and does not do.

The FDA does not independently test drugs. It reviews data submitted by the companies that made those drugs, and those companies pay over four million dollars per application for that review to happen, and those fees collectively fund nearly two thirds of the entire human drug review operation. The agency evaluating whether your medication is safe is financially dependent on the companies selling it.

Then after that review is complete, those same agency officials frequently go work for those companies. A 2018 analysis published in Science found that 62% of FDA medical officers who left the agency between 2006 and 2019 went directly into jobs in the pharmaceutical industry. The FDA commissioner from 2017 to 2019 left and joined Pfizer's board of directors the same year he stepped down. This pattern has a name: the revolving door. And it creates a situation where the people making regulatory decisions know their next career move likely depends on staying friendly with the industry they are supposed to be watching.

Outside the agency itself, pharmaceutical companies spend $374 million a year on federal lobbying, which is more than any other industry in the country, and they maintain roughly three lobbyists for every single member of Congress.

This is not a broken system. It is the system working exactly as it was designed to work.

Now here is where peptides come in, and why this matters for anyone who has ever heard an influencer use FDA approval as the reason to avoid research chemicals.

Peptides are short chains of amino acids, which are the same building blocks that make up proteins, and many of the most studied ones are sequences that either occur naturally in the human body or mirror structures the body already produces. That matters because of how pharmaceutical patents work. A naturally occurring peptide sequence cannot be patented. You cannot own a molecular structure that nature made first.

The standard estimate for bringing a new drug through FDA approval is somewhere around $985 million in capitalized research and development costs, according to a 2020 analysis published in JAMA Internal Medicine. No company is going to spend close to a billion dollars running clinical trials for a compound that any competitor can manufacture the moment it clears approval because there is no patent protection, no exclusivity, and no way to recover that investment. The economics simply do not work.

So the reason research peptides will never carry an FDA approval has nothing to do with whether they are safe or effective. It has to do with whether a pharmaceutical company can make money owning them, and the answer is no, so the money never gets spent, so the approval never happens, so the compound stays in the research category indefinitely, regardless of what the actual science says.

That is a structure built entirely around profit, not safety.

Which brings us to the influencer who uses FDA approval as the reason you should not trust research peptides, while also running a business that sells peptides sourced through compounding pharmacies.

Compounding pharmacies operate under a different FDA framework than standard drug approvals. They can produce substances that have not gone through the full approval process, and a peptide sourced through a compounding pharmacy carries no more FDA approval than a research chemical does. The regulatory difference between the two is much smaller than it is being presented, and anyone selling compounding pharmacy peptides while telling you research chemicals are dangerous because they lack FDA oversight is using the credibility of a corrupt system selectively, as a marketing tool, not as a genuine safety standard.

The position requires you to believe the FDA is a reliable authority on safety when it supports the business, and a system worth ignoring when it does not. You cannot hold both of those things at the same time with any intellectual honesty.

The deeper problem is that the FDA's actual record makes it a strange authority to invoke for anyone claiming to prioritize your health. This is the same system that approved opioids at scale, that continues to allow food additives banned in dozens of other countries, and that has a structural incentive to approve pharmaceutical solutions over lifestyle interventions because lifestyle interventions do not generate application fees.

No politician fixes this. The pharmaceutical industry contributes billions annually to the federal government across both parties and across decades. The financial relationship between drug companies, regulators, and legislators is not a policy problem you vote away. It is the architecture of the system.

What you actually have when you look at the research peptide space is a category of compounds that are scientifically interesting, that cannot get approved because no one will pay for approval, that are being studied in academic and research contexts at a growing rate, and that some people are using with no corporate intermediary taking a cut, which is exactly the problem for anyone whose business depends on being that intermediary.

The FDA stamp does not mean safe. It means someone spent close to a billion dollars making the case that a compound is approvable under a system funded by the people making that case. Those are very different things, and conflating them is either confused thinking or deliberate misdirection. When the person doing it is also selling you an alternative product, you should probably figure out which one it is.

---

References

1. FDA PDUFA Fee Schedule — Federal Register (published annually). FY 2024 application fee: $4,198,000.
2. FDA Budget Justification to Congress — PDUFA user fees fund approximately 65% of CDER/CBER human drug review budget.
3. Piller, C. (2018). "Is FDA's revolving door open too wide?" Science. Found 62% of FDA medical officers who left between 2006-2019 went to work for pharmaceutical industry.
4. OpenSecrets.org — Center for Responsive Politics. Pharmaceutical/health products industry spent $374 million on federal lobbying in 2023, #1 ranked industry. Approximately 1,500-1,800 registered lobbyists (roughly 3:1 ratio to members of Congress).
5. Scott Gottlieb served as FDA Commissioner 2017-2019, joined Pfizer board of directors in 2019.
6. Wouters, O.J., McKee, M., Luyten, J. (2020). "Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018." JAMA Internal Medicine. Median capitalized cost: $985 million per drug.

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness